Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

2.52 EUR

+0.20 %

5,650 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.20 %
-12.67 %
-33.29 %
-31.75 %
-32.84 %
-32.93 %
-32.03 %
-57.45 %
-45.09 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
53.96M EUR
Turnover
73.49K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
11.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Mr. Huhtinen’s summary of the China trip. Apparently a successful trip. A bold statement in the post: ”I’m convinced we will succeeded​” Already in Spain pitching now…. You’re starting to get a real sense of a “can-do” attitude​ LinkedIn #screening #prevention #diabeticretinopathy...
yesterday
by Mr. Stock
36
The annual general meeting is still two months away. A lot can happen before then, or perhaps not. In any case, I don’t feel it’s necessary to start advising or reprimanding the CEO. Rather, I’m trying to better understand Optomed’s future and whether the market is pricing Optomed...
3/11/2026, 4:31 PM
by Tero Ahola
27
In Canada as well, screenings are being done with a handheld camera + assistive (i.e., not diagnostic) AI. I would guess that an Optomed camera is being used. Both Aurora and Lumo have Health Canada marketing authorizations. Only EyeArt has approval in Canada for diagnostic AI. —...
yesterday
by Sheikki
22
Nordnet Seurantalista: Varakkaiden suomalaisten ostokohteet Rahamääräisesti netto-ostetuimmat osakkeet, rahastot ja ETF:t Nordnet Suomen varakkaassa Private Banking -segmentissä edelliskuussa, alkaen ostetuimmasta. Optomed is on the list. Ketchup bottle effect soon?
22 hours ago
by kivimies
19
The main message of the post is that ophthalmology AI is currently the most advanced and practically functional field of medical AI. The event was at Johns Hopkins, which is constantly mentioned in this scene…. LinkedIn Ophthalmology AI is the crown jewel of medical AI. It's the ...
yesterday
by Mr. Stock
15
Put the CEO on the hot seat; where are our promised big customers, Top 10 Pharmas and Lumo’s FDA, among others?
3/11/2026, 11:31 AM
by Mr. Stock
9
Medicare Advantage payments will increase in 2026, boosting funding for private Medicare Advantage insurers. The payment increase supports preventive care and the achievement of quality metrics (Star Ratings, HEDIS), such as diabetic eye exams. LinkedIn Medicare Advantage News: The...
23 hours ago
by Mr. Stock
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.